Demonstrated efficacy of our OPMD would attract many new...

Demonstrated efficacy of our OPMD would attract many new investors betting on a takeover at a significant premium (often double the company's value by recent examples). Investors don't wait for commercialization but expect big pharma to swoop down and buy the product or company usually a low-floating, thinly-traded micro-cap. 

What if Benitec's pre-clinical research in other indications is very promising? Perhaps the board is in discussions now with big pharma and just about to ink a deal similar to the Axovant deal but with a much bigger upfront payment. And when an announcement is made what would that do to the share price. That is why I believe we are looking at a multi-bagger. OPMD is the tip of the iceberg.